Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T22:17:34.395Z.
Consensus retrieved: 2026-10-06T13:25:02.493Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T22:17:34.395Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e161c80cfac107eb20fb361b69cb0f235817b8c251747178931ba3815a78b5f6
Forward PE Ratio (N/A) = Dated Quote Price ($2.73) / Consensus Forward EPS ($-0.52)
FORWARD PE RATIO
N/A
LifeMD, Inc.
Market Cap
$132.03M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| LifeMD, Inc. (LFMD) | $132.03M | N/A |
| AirSculpt Technologies, Inc. (AIRS)vs › | $131.21M | N/A |
| Health Catalyst, Inc. (HCAT)vs › | $130.79M | N/A |
| Freenome, Inc. (FRNM)vs › | $133.45M | N/A |
| Pyxis Oncology, Inc. (PYXS)vs › | $127.98M | N/A |
| Organigram Global Inc. (OGI)vs › | $136.57M | N/A |
| Atrium Therapeutics, Inc. (RNA)vs › | $136.67M | N/A |
| NRx Pharmaceuticals, Inc. (NRXP)vs › | $127.29M | N/A |
| KORU Medical Systems, Inc. (KRMD)vs › | $137.80M | N/A |
| Immuneering Corporation (IMRX)vs › | $139.04M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $2.73, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.52 | $-0.54 – $-0.50 | 3 | n/m |
| 2027-12-31 | $-0.09 | $-0.16 – $-0.01 | 3 | n/m |
| 2028-12-31 | $0.15 | $-0.02 – $0.34 | 5 | 18.0x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
